The Journal of Experimental Medicine
VeriKine-HS Human IFN-Beta
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 6 August 2001. doi:10.1084/jem.194.3.235
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 170K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bottino, C.
Right arrow Articles by Moretta, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bottino, C.
Right arrow Articles by Moretta, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/2001/8/235/ $5.00
The Journal of Experimental Medicine, Volume 194, Number 3, August 6, 2001 235-246


Original Article

Gntb-A, a Novel Sh2d1a-Associated Surface Molecule Contributing to the Inability of Natural Killer Cells to Kill Epstein-Barr Virus–Infected B Cells in X-Linked Lymphoproliferative Disease

Cristina Bottinoa, Michela Falcob, Silvia Parolinic, Emanuela Marcenarob, Raffaella Augugliaroa, Simona Sivorib, Elena Landib, Roberto Biassonia, Luigi D. Notarangelod, Lorenzo Morettab,e, and Alessandro Morettab

a Istituto Nazionale per la Ricerca sul Cancro, 16132 Genova, Italy
b Dipartimento di Medicina Sperimentale, Università di Genova, 16132 Italy
c Dipartimento di Scienze Biomediche e Biotecnologie, Clinica Pediatrica, Università di Brescia, Brescia 25123 Italy
d Istituto di Medicina Molecolare Angelo Nocivelli, Clinica Pediatrica, Università di Brescia, Brescia 25123 Italy
e Istituto Giannina Gaslini, 16148 Genova, Italy
Dipartimento di Medicina Sperimentale, Sezione di Istologia, Via G.B. Marsano 10, 16132 Genova, Italy.39-010-51-27-4739-010-35-37-868

alemoret{at}unige.it

In humans, natural killer (NK) cell function is regulated by a series of receptors and coreceptors with either triggering or inhibitory activity. Here we describe a novel 60-kD glycoprotein, termed NTB-A, that is expressed by all human NK, T, and B lymphocytes. Monoclonal antibody (mAb)-mediated cross-linking of NTB-A results in the induction of NK-mediated cytotoxicity. Similar to 2B4 (CD244) functioning as a coreceptor in the NK cell activation, NTB-A also triggers cytolytic activity only in NK cells expressing high surface densities of natural cytotoxicity receptors. This suggests that also NTB-A may function as a coreceptor in the process of NK cell activation. Molecular cloning of the cDNA coding for NTB-A molecule revealed a novel member of the immunoglobulin superfamily belonging to the CD2 subfamily. NTB-A is characterized, in its extracellular portion, by a distal V-type and a proximal C2-type domain and by a cytoplasmic portion containing three tyrosine-based motifs. NTB-A undergoes tyrosine phosphorylation and associates with the Src homology 2 domain–containing protein (SH2D1A) as well as with SH2 domain–containing phosphatases (SHPs). Importantly, analysis of NK cells derived from patients with X-linked lymphoproliferative disease (XLP) showed that the lack of SH2D1A protein profoundly affects the function not only of 2B4 but also of NTB-A. Thus, in XLP-NK cells, NTB-A mediates inhibitory rather than activating signals. These inhibitory signals are induced by the interaction of NTB-A with still undefined ligands expressed on Epstein-Barr virus (EBV)-infected target cells. Moreover, mAb-mediated masking of NTB-A can partially revert this inhibitory effect while a maximal recovery of target cell lysis can be obtained when both 2B4 and NTB-A are simultaneously masked. Thus, the altered function of NTB-A appears to play an important role in the inability of XLP-NK cells to kill EBV-infected target cells.

Key Words: X-linked lymphoproliferative disease • coreceptors function • natural killer cells • Epstein-Barr virus • Src homology 2 domain–containing protein


Abbreviations used in this paper: Ig-SF, Ig superfamily; ITAM, immune tyrosine-based activating motif; ITIM, immune tyrosine-based inhibitory motif; KIR, killer inhibitory receptor; LAT, linker for activation of T cells; NCR, natural cytotoxicity receptor; RT, reverse transcription; XLP, X-linked lymphoproliferative disease.

C. Bottino, M. Falco, and S. Parolini contributed equally to this work.

© 2001 The Rockefeller University Press


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS